D J Colin1, E Limagne2, K Ragot3, G Lizard3, F Ghiringhelli4, É Solary5, B Chauffert4, N Latruffe3, D Delmas2. 1. 1] Université de Bourgogne, Dijon F-21000, France [2] Centre de Recherche Inserm U866-Lipids, Nutrition, Cancers, Dijon F-21000, France [3] EA7270-Bio-PeroxIL Biochimie du peroxysome, inflammation et métabolisme lipidique, Dijon F-21000, France. 2. 1] Université de Bourgogne, Dijon F-21000, France [2] Centre de Recherche Inserm U866-Lipids, Nutrition, Cancers, Dijon F-21000, France. 3. 1] Université de Bourgogne, Dijon F-21000, France [2] EA7270-Bio-PeroxIL Biochimie du peroxysome, inflammation et métabolisme lipidique, Dijon F-21000, France. 4. 1] Université de Bourgogne, Dijon F-21000, France [2] Centre de Recherche Inserm U866-Lipids, Nutrition, Cancers, Dijon F-21000, France [3] Centre de Lutte Contre le Cancer GF Leclerc, Dijon F-21000, France. 5. Inserm UMR 1009, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif cedex, France.
Abstract
In spite of the novel strategies to treat colon cancer, mortality rates associated with this disease remain consistently high. Tumour recurrence has been linked to the induction of resistance towards chemotherapy that involves cellular events that enable cancer cells to escape cell death. Treatment of colon cancer mainly implicates direct or indirect DNA-damaging agents and increased repair or tolerances towards subsequent lesions contribute to generate resistant populations. Resveratrol (RSV), a potent chemosensitising polyphenol, might share common properties with chemotherapeutic drugs through its indirect DNA-damaging effects reported in vitro. In this study, we investigated how RSV exerts its anticancer effects in models of colon cancer with a particular emphasis on the DNA-damage response (DDR; PIKKs-Chks-p53 signalling cascade) and its cellular consequences. We showed in vitro and in vivo that colon cancer models could progressively escape the repeated pharmacological treatments with RSV. We observed for the first time that this response was correlated with transient activation of the DDR, of apoptosis and senescence. In vitro, a single treatment with RSV induced a DDR correlated with S-phase delay and apoptosis, but prolonged treatments led to transient micronucleations and senescence phenotypes associated with polyploidisation. Ultimately, stable resistant populations towards RSV displaying higher degrees of ploidy and macronucleation as compared to parental cells emerged. We linked these transient effects and resistance emergence to the abilities of these cells to progressively escape RSV-induced DNA damage. Finally, we demonstrated that this DNA damage was triggered by an overproduction of reactive oxygen species (ROS) against which cancer cells could adapt under prolonged exposure to RSV. This study provides a pre-clinical analysis of the long-term effects of RSV and highlights ROS as main agents in RSV's indirect DNA-damaging properties and consequences in terms of anticancer response and potent resistance emergence.
In spite of the novel strategies to treat colon cancer, mortality rates associated with this disease remain consistently high. Tumour recurrence has been linked to the induction of resistance towards chemotherapy that involves cellular events that enable cancer cells to escape cell death. Treatment of colon cancer mainly implicates direct or indirect DNA-damaging agents and increased repair or tolerances towards subsequent lesions contribute to generate resistant populations. Resveratrol (RSV), a potent chemosensitising polyphenol, might share common properties with chemotherapeutic drugs through its indirect DNA-damaging effects reported in vitro. In this study, we investigated how RSV exerts its anticancer effects in models of colon cancer with a particular emphasis on the DNA-damage response (DDR; PIKKs-Chks-p53 signalling cascade) and its cellular consequences. We showed in vitro and in vivo that colon cancer models could progressively escape the repeated pharmacological treatments with RSV. We observed for the first time that this response was correlated with transient activation of the DDR, of apoptosis and senescence. In vitro, a single treatment with RSV induced a DDR correlated with S-phase delay and apoptosis, but prolonged treatments led to transient micronucleations and senescence phenotypes associated with polyploidisation. Ultimately, stable resistant populations towards RSV displaying higher degrees of ploidy and macronucleation as compared to parental cells emerged. We linked these transient effects and resistance emergence to the abilities of these cells to progressively escape RSV-induced DNA damage. Finally, we demonstrated that this DNA damage was triggered by an overproduction of reactive oxygen species (ROS) against which cancer cells could adapt under prolonged exposure to RSV. This study provides a pre-clinical analysis of the long-term effects of RSV and highlights ROS as main agents in RSV's indirect DNA-damaging properties and consequences in terms of anticancer response and potent resistance emergence.
In spite of chemotherapy and systematic screening for people at risk, the mortality rate
of colorectal cancer (CCR) remains high and stable, with 6 00 000 deaths
per year. The 5-year survival ranges from 90% in patients with stage I to
10% in patients with stage IV disease.[1]
This low success rate in the treatment of CCR results from many failures associated with
high resistance and the risk of metastasis. Resistance has been related to the
adaptations that inhibit the ability of tumour cells to die by apoptosis. These
adaptations are well known to implicate other mechanisms that control the
pro-survival/pro-apoptotic balance including autophagy and senescence.[2, 3] Senescence
constitutes a powerful resistance mechanism towards CCR chemotherapy, which typically
involves DNA-damaging agents nowadays.[4] Indeed,
cancer cells respond to DNA damage by initiating the DNA-damage response (DDR), which
induces cell cycle delay, more prolonged growth arrests (senescence) and apoptosis of
the lethally damaged cells. The DDR is initiated by the phosphatidylinositol
3-kinase-related kinases (PIKKs) ATM, ATR and DNA-PKcs that elicit DNA repair,
concomitant cell cycle progression and apoptosis regulations through the
Chk1/2-p53-p21 signalling cascade.[5]One promising approach to counteract chemoresistance could be the use of adjuvants.
Among them, resveratrol (trans-3,4′,5-trihydroxystilbene; RSV) has been shown to
prevent or delay the different steps of carcinogenesis[6, 7] through its capacity to
inhibit cell cycle progression, to induce apoptosis,[8, 9] autophagic-related cell
death[10] and senescence via DNA
damage.[11, 12] Because of its low toxicity in animal models[6] and in humans[13,
14, 15], RSV
has been proposed as a potent adjuvant to sensitise cancer cells to various anticancer
drugs,[16, 17,
18] cytokines (e.g. TRAIL),[19] and ionising radiation.[20] Recently, phase I/II clinical trials have shown that
administration of RSV was correlated with a 5% reduction of tumour growth in
patients with confirmed CCR, despite its low bioavailability in its unmetabolised
form.[21] Accordingly, we have proved
in vitro that RSV metabolites were able to induce the DDR, subsequent
S-phase delay and apoptosis and improved the efficacy of anticancer drugs.[22]Considering that RSV behave as an apparent DNA-damaging agent, we investigated its
long-term effects towards CCR models with a particular emphasis on its DNA-damaging
properties and the related consequences in vitro and in vivo in terms
of resistance. We demonstrated that RSV-induced DNA damage was triggered by an
overproduction of reactive oxygen species (ROS) against which cancer cells could adapt
under prolonged exposure to RSV. These effects have to be considered pre-clinically to
further point out RSV as a potent chemosensitising agent.
Results
Transient DNA-damage response is associated with a resistance towards
resveratrol treatments in models of CCR in vivo
First, we determined the effects of the daily administrations of pharmacological
doses of RSV to syngeneic rats bearing subcutaneous PROb CCR. Our results showed
that RSV failed to delay the growth of tumours at 40 mg/kg per day
either by beginning the treatments 2 or 14 days after the injection of PROb cells
(Figure 1a). To further investigate this
controversial result, a higher dose of 200 mg/kg per day was used and
did not statistically interfere with tumour growth as well. Overall, these first
results showed that RSV effects towards PROb tumours did not agree with other
studies, although the doses used produced plasma levels of free and metabolised
RSV compatible with anticancer effects reported on CCR[22] and on other models[6] (Figure 1a, inserts).
Figure 1
Resveratrol promotes transient accelerated senescence and apoptosis in
vivo. (a) Effects of daily oral administrations of 40 and
200 mg/kg of RSV on the growth of PROb tumours in vivo. PROb
cells were subcutaneously injected at day 0 to BD-IX rats and the treatments with
RSV or with the vehicle (Ctl) began at day 2 or 14. Data are medians of tumour
volumes of nine rats per group±the first and third quartile of one
representative experiment among three. No statistically significant differences
were found by the Mann–Whitney's test. Inserts show the
median±the first and third quartile of plasma concentrations of free and
metabolised RSV measured 1 h after the last administration of RSV to the
rats of the experiment shown. (b) Microscopic evaluation of DNA
fragmentation by TUNEL staining in PROb tumours. Pixels intensities were measured
on 10 random microscopic fields of five tumours per group and is plotted as mean
intensity±S.D. and compared with control tumours (Ctl). (c)
Microscopic evaluation of SA-β-galactosidase activity in PROb
tumours resected after 7 and 10 days of daily treatments with 200 mg/kg
of RSV (R200). Negative pixels intensities measurement related to
SA-β-galactosidase staining were performed as described above.
Typical microscopic fields are shown on the left; bar,
100 μm. On both panels, statistical significance was
determined by the Student's t-test with P<0.05 (*),
P<0.01 (**) and P<0.001 (***)
To further explore the unexpected response of this in vivo model, we
assessed if this apparent lack of effect was associated with an absence of early
macroscopic effects in tumours. Surprisingly, after 7 and 10 days of treatments, a
significant but transient induction of apoptosis was observed (Figure 1b). Also, senescence was robustly induced by RSV (Figure 1c). This increase strongly diminished with the time
of treatment while remaining significant compared with the control.Transient inductions of apoptosis and senescence have been correlated with the
emergence of tumour resistance towards a plethora of therapies, including
DNA-damaging agents.[2, 3] Here, after 7 days of treatment, RSV induced an overall
activation of the DDR (Figures 2a and b). We observed
an increase of the phosphorylation of the histone H2AX (γH2AX),
which is a marker of single and double-stranded DNA breaks. Indeed, the PIKKs
(ATM, ATR and DNA-PK) phosphorylate this histone to prime damaged DNA for repair
and initiate the DDR. In agreement, RSV further induced the cascade of
phosphorylations involving the checkpoint kinases Chk1 and Chk2 and ultimately
leading to the stabilisation of p53 through its phosphorylation on its Ser18.
Thus, p53 played its transcription factor role as shown by the overexpression of
its target p21 in treated tumours. p21 is known to be implicated in the cell
death–cell survival balance and its overexpression has also been linked to
senescence induction concomitantly with the important mediator p16.[23] Accordingly, p16 was slightly overexpressed
in RSV-treated tumours. RSV-induced caspase-3 activation (Figure 2) confirmed apoptosis induction (Figure
1b). Importantly, these activations were transient, since after 10
days of treatment most of these inductions became statistically undetectable
(Figures 2c and d).
Figure 2
Resveratrol induces a transient activation of the DNA-damage response in
vivo. Levels of expression and phosphorylation of the components of the
DNA-damage response were analysed by immunoblotting using the specified
antibodies. Analyses were performed on PROb tumours extracts collected from five
rats per group after 7 (a) and 10 days (c) of daily treatments with
200 mg/kg of RSV (R200) and compared to control tumours (Ctl).
Quantifications by densitometry (b, d) are plotted as
medians±the first and third quartile. Statistical analyses were performed
by the Mann–Whitney's test and are shown as significant with
P<0.05 (*) and P<0.01 (**)
These results correlating transient DDR, apoptosis and senescence activations by
RSV led us to explore the response of a more standard model of human CCR xenograft
in Nude mice. We used the SW620 model which has already exhibited sensitivity
towards RSV in vitro (Supplementary Table
S1). In contrast to the PROb model, RSV treatment led to a growth
delay of SW620 tumours (Figure 3a), showing the
model-dependent macroscopic effects of RSV. Interestingly, the extent of this
delay appeared to decrease with time according to the statistical analysis. We
biochemically characterised the response of this model and found a similar trend
in terms of DDR induction as compared with the PROb model (Figures 3b and c). Indeed, all the markers described earlier were
induced in RSV-treated tumours, including the senescence p16 and apoptosis
caspase-3 markers. Importantly, after 15 days of treatment, most of these
inductions were compromised, which agreed with what we found in the PROb
model.
Figure 3
Resveratrol induces a transient activation of the DNA-damage response in
vivo. (a) Effects of daily oral administrations of
200 mg/kg of RSV on the growth of SW620 tumours in vivo. SW620
cells were subcutaneously injected at day 0 to nude mice and the treatments with
RSV or with the vehicle (Ctl) began at day 2. Data are medians of tumour volumes
of 9–12 mice per group±the first and third quartile. Statistical
analyses were performed by the Mann–Whitney's test and are shown as
significant with P<0.05 (*) and P<0.01 (**).
(b, c) Levels of expression and phosphorylation of the components
of the DNA-damage response were analysed by immunoblotting using the specified
antibodies. Analyses were performed on SW620 tumours extracts collected from five
mice per group after 11 (b) and 15 days (c) of daily treatments with
200 mg/kg of RSV (R200) and compared to control tumours (Ctl).
Quantifications by densitometry are plotted as medians±the first and third
quartile. Statistical analyses were performed by the Mann–Whitney's
test and are shown as significant with P<0.05 (*) and
P<0.01 (**)
Overall, these results demonstrate that in vivo models of CCR treated by
RSV can progressively escape its pro-apoptotic and pro-senescence effects, and
that this resistance phenomenon is correlated with a short-term DDR induction.
Repeated treatments with resveratrol induce a polyploidisation and an escape
of colon cancer cells from its antiproliferative effects
These observations led us to further characterise the long-term response of PROb
and SW620 cells in vitro. We analysed the antiproliferative effects of
RSV using a 30 μM concentration which has been widely described
to induce growth arrests and cell death of CCR cells[18, 24] without causing
cytotoxicity in normal cells[25]
(Supplementary Table 1). A single treatment of
cells with RSV slowed down their proliferation for 4 days (Figure 4a). A second treatment at day four showed that RSV was not
able to further inhibit cell growth, which restarted from day 6 for PROb and more
progressively for SW620 cells, indicating that these cell lines became gradually
resistant. To assess this phenomenon, we performed chronic treatments with RSV
every 4 days for 2 months, resulting in the isolation of two stable populations,
R2PROb and R2SW620 cells. According to their
IC50 values, these populations were less sensitive towards RSV and
they grew similarly to the parental cells even in the presence of R30 (Figure 4a, Supplementary Table
1).
Figure 4
Repeated treatments with resveratrol lead to a polyploidisation and the emergence
of a resistance. (a) Growth curves of colon cancer parental cells PROb and
SW620 treated with 30 μM of RSV (R30) at days 0 and 4 or left
untreated (Ctl); proliferation of resistant cells R2PROb and
R2SW620 obtained after 4-days pulses of R30 during two months is
also presented. (b) Representative cell cycle analyses by PI/BrdU
stainings of PROb and SW620 cells mock-treated (Ctl) or treated with R30 for 1 day
(d1) and 5 days (d5). (c) Cumulative histograms (numbers shown are means)
showing cell distribution in the different phases of their cell cycle after
indicated times of R30 treatments in days (d). Flow cytometry gating procedure is
depicted in B. Data are means±S.D. of three independent experiments
To understand this escape, we analysed the effects of repeated RSV treatments on
the cell cycle progression. RSV induced a rapid accumulation of parental cell
lines in the S phases of the diploid and tetraploid cell cycles after 24 h
(Figures 3b and c, denoted BrdU+). A second
pulse at day 4 was less efficient in delaying S-phase progression, especially in
PROb cells, showing a progressive loss of effects. Importantly, from three days of
treatment, cells acquired a higher level of ploidy (Figures 4b
and c, Supplementary Figure S1). Also,
in the resistant R2PROb and R2SW620 populations, in which
cell cycle progressions were not affected by RSV, the percentages of polyploid
cells were higher than in parental cell lines. Loss of sensitivity towards RSV is
therefore associated with an early and transient delay in S-phase progression and
a robust generation of polyploid cells enriched in stable resistant
populations.
Resveratrol transiently induces cell death and senescence in colon cancer
cells
As chronic RSV treatment temporally induced apoptosis and senescence in
vivo (Figure 1a), we precisely analysed the
phenotypic consequences of long-term treatments in vitro. We found that
RSV could induce three major nuclear phenotypes as compared with
‘normal' nuclei in terms of size and morphology: cells exhibiting
enlarged nuclei denoted as macronucleated; multinucleated ones; and apoptotic
cells with bright condensed or fragmented nuclei (Figures 5a
and b). After three days, RSV-induced apoptosis in PROb (29%)
and SW620 (49%) cells. Nevertheless, the second pulse of RSV at day four
barely induced any apoptosis suggesting that apoptosis induction by RSV is only a
transient effect. These results were confirmed by Annexin V / Propidium Iodide
staining which showed the temporal induction of apoptosis and its progression
(early apoptosis AV+/PI-; late apoptosis and secondary necrosis
AV+/PI+), but no necrosis could be detected (AV-/PI+)
(Supplementary Figure S2). Moreover, we found a
transient increase of viable cells displaying macronucleations (peaking at
48% of cells at day 5), which could be linked to the progressive
polyploidisation in duced by RSV (Figure 4c). In
addition, a significant proportion of PROb cells became progressively
multinucleated resulting in an amount of 28% of cells after 7 days of
treatment, while this phenomenon was much reduced in SW620 cells. Macro- and
multinucleated cells were mostly viable since they rarely appeared positive for
TUNEL staining. Accordingly, we found high basal amounts of viable macro- and
multinucleated cells in the isolated R2PROb- and
R2SW620-resistant populations which correlated with their high level of
polyploidy (Figure 4c). Finally, RSV-treated resistant
cells displayed a very-low rate of apoptosis (Figures 5a and
b, Supplementary Figure S2), and
further increases of macro- and multinucleations were milder as compared with
parental cells, showing that RSV did not really affect the phenotype of these
populations.
Figure 5
Resveratrol transiently induces cell death and senescence in colon cancer cells.
(a,b) Analyses of the phenotypic responses of PROb and SW620
cells and of the isolated resistant towards RSV populations R2PROb and
R2SW620. Cells were treated with 30 μM of RSV
(R30) for indicated times and analysed by Hoechst 33342 and TUNEL co-stainings. On
the left, representative fields showing typical features observed by microscopic
analyses of cytospun cells, cells with normal nuclei (N), macronucleated (M),
multinucleated (MN) and apoptotic ones; bar, 20 μm. On
the right, cumulative histograms (numbers shown are means) showing the percentages
of the different morphologies observed after indicated times of treatments in days
(d) with R30 or mock-treated (Ctl). (c) Microscopic evaluation of
SA-β-galactosidase activity in cells treated with R30.
Representative microscopic observations are shown on the left after 5 days of R30
(d5); bar, 40 μm. Percentages of
SA-β-galactosidase positive cells after indicated times of R30
treatments in days are shown on the histograms on the right. Data in both panels
are means±S.D. determined by counting 300 cells in three independent
experiments. Statistical significance was determined by the Student's
t-test with P<0.001 (***)
Degrees of macrocytosis and multinucleation have been linked to drug-induced
senescence, a phenotype we found in PROb tumours in vivo (Figure 1c). Our experiments demonstrated that RSV strongly
but transiently induced senescence in CCR cells (Figure
5c). Senescence levels peaked at day 5, in accordance with the maximum
level of macro- and multinucleated cells. As expected, these cells were almost all
positive for the SA-β-galactosidase staining. Also, senescence
induction was not lethal since no cell death was detected when this rate
progressively decreased. Interestingly, RSV-treated resistant populations did not
induce this mechanism, demonstrating that resistance implied a loss of sensitivity
towards its pro-senescent activity.Overall, we showed that repeated treatments with RSV of PROb and SW620 CCR cells
firstly induced apoptosis then transient senescence in the remaining macro- and
multinucleated viable cells.
Resveratrol induces a short-term replication stress and subsequent
DNA-damage signalling in colon cancer cell lines
Resistance emergence towards RSV in CCR appeared to be related to a loss of
sensitivity towards its pro-apoptotic and pro-senescence activities associated
with a transient DDR induction in vivo. Thereafter, we took advantage of
this new in vitro sensitive/resistant model to further characterise
the DNA-damaging effects of RSV. To decipher the sequence of these events, we
assessed the induction of γH2AX in a cell cycle-dependent manner.
After 24 h of treatment, ~70% of RSV-treated cells exhibited high
levels of γH2AX (Figure 6a). Most of
the γH2AX positive cells had diploid or tetraploid S-phase DNA
contents, which is a hallmark of cells under replication stress. Microscopic
analyses demonstrated typical γH2AX foci after treatments and
highly positive apoptotic cells as γH2AX is known to be involved in
this process (Figure 6b). Finally, as the
γH2AX induction appeared to be highly transient in RSV-treated
resistant populations (Supplementary Figure S3),
we hypothesised that RSV could generate a replication stress in sensitive cells
which would ultimately adapt to this damaging effect.
Figure 6
Resveratrol promotes the phosphorylation of the DNA-damage marker histone H2AX.
(a) Flow cytometric analyses of γH2AX/PI staining on
PROb and SW620 cells after 1 day of treatment (d1) with 30 μM
of RSV (R30) or mock-treated (Ctl); the percentages represent the amounts of
γH2AX positive cells. (b) Microscopic analysis of
γH2AX immunostainings of PROb cells grown on coverslips treated
with R30 during 1 (d1) or 3 days (d3). Arrows show macronucleated cells (M) and
apoptotic ones (A); bars, on the left 100 μm, on the
right 20 μm. (c, d) Time course of expression and
phosphorylation of the components of the ATR, ATM and DNA-PK pathways were
analysed by immunoblotting using the specified antibodies. PROb and SW620 cells as
well as their resistant counterpart, R2PROb and R2SW620
populations, were treated with R30 for indicated times in days (d) and compared
with the untreated cells (Ctl)
To confirm this hypothesis, we further studied RSV effects on the regulation of
the DDR in a time-dependent manner. In parental cell lines, a global and transient
induction of these pathways was observed since DNA-PKcs, Chk1 and Chk2 were
phosphorylated on activation sites (Figures 6c and d).
In terms of time course, it was noticeable that Chk1 was activated prior to Chk2,
consistent with a rapid replication stress/single strand break signalling
which is mediated by ATR. Consequently, the main downstream mediator of these
pathways, p53, was phosphorylated on its Ser15 (Ser18 in rodents), which was
associated with an overexpression of p21Cip1 and p16INK4A.
In resistant populations, these activations were compromised. Overall, these
results showed that following an early replication stress, RSV induced a DDR in
CCR cells concomitant with an S-phase delay and apoptosis followed by transient
senescence in a long-term manner. Moreover, as the DDR activation was impaired in
isolated resistant populations, we concluded that RSV anticancer properties highly
depended on its DNA-damaging effects and subsequent cancer cell responses.
DDR inhibitions enhance RSV anticancer activity in sensitive and resistant
colon cancer cells
To characterise the involvement of the DDR in RSV anticancer properties, we used
specific kinases inhibitors. Caffeine, which inhibits all the PIKKs or SB218078
which targets Chk1, synergised with RSV in reducing CCR cells viability after
24 h, while ATM inhibitor KU55933 and DNA-PKcs inhibitor NU7026 did not
(Figure 7a). After 72 h, pre-treatments with
all these inhibitors more than doubled the level of apoptosis and highly reduced
polyploidy (Figure 7b). These time-related effects of
the inhibitors showed the implication of two axes of the DDR in response to
RSV-induced replication stress, ATR-Chk1 then DNA-PK/ATM-Chk2 depicted above
(Figure 6). Accordingly, after 72 h, caffeine or
Chk1i enhanced RSV-induced γH2AX levels, which
indicated cell cycle checkpoints abrogation, subsequent lack of DNA-damage repair
(shown by enhanced Chk2 phosphorylation, Figure 7c)
and apoptosis (Figure 7b). Then, inhibitions of these
kinases partly restored RSV activity towards resistant cells showing that their
lack of response might be linked to their ability to react to RSV-induced DNA
damage (Figure 7a). Interestingly, resistant cells
were not more sensitive to other DNA-damaging agents used to treat CCR, since we
did not detect any cross-resistance towards 5-fluoro-uracil, oxaliplatin and SN-38
(Supplementary Table S1). However, the
antiproliferative effects of doxorubicin were compromised in cells resistant
towards RSV showing that these two compounds might share common mechanisms of
action. Altogether, these results demonstrated that RSV-induced DDR and subsequent
checkpoint activation in sensitive cells was responsible for its transient
anticancer effects. They also show that prolonged RSV treatments and subsequent
resistance emergence directly or indirectly depends on its DNA-damaging
effect.
Figure 7
Resveratrol effects are linked to the activation of the DNA-damage response.
(a) Sensitising effects of specific inhibitors of major kinases involved
in the DNA-damage response on the growth of parental and resistant colon cancer
cells treated with 30 μm RSV (R30) for 24 h. Cells were
pre-treated for 2 h with the PIKKs inhibitor caffeine (Caff), Chk1
inhibitor SB218078 (Chk1i), ATM inhibitor KU55933 (ATMi) or
DNA-PK inhibitor NU7026 (DNA-PKi). (b) Cell cycle analysis by PI
staining of cells treated for 72 h with R30 and with the different
inhibitors as described before. Flow cytometry analysis was performed by gating
SubG1, diploid (2N) and polyploid (>4N) cells as shown on the 1D plots. Data
shown in A and B are means±S.D. of three independent experiments.
(c) Levels of expression and phosphorylation of components of the
DNA-damage response analysed by immunoblotting using the specified antibodies.
PROb and SW620 cells were treated with the specified inhibitors as described
above
Reactive oxygen species mediate RSV-induced DNA damage and subsequent
effects
ROS are known to induce replication stress and DNA damage[26] and are implicated in the anticancer effects of potent
chemotherapeutic drugs (e.g. doxorubicin). RSV is usually described as an
antioxidant, but as it induced replication stress and shares properties with
doxorubicin, it seemed important to study the role of ROS in RSV effects. Thus,
using a H2DCFDA probe, we found that RSV efficiently induced an
overproduction of ROS in CCR cells (Figure 8a).
Furthermore, mitochondrial O2- was measured using a MitoSOX
probe and was found to be overproduced. These productions were counteracted by
antioxidants like reduced glutathione, N-Acetylcystein and Trolox.
Moreover, these antioxidants partly inhibited RSV antiproliferative effects
(Figure 8b). Antioxidants also counteracted the
DNA-damaging effects of RSV as well as apoptosis induction as revealed by
γH2AX, p21 and cleaved caspase-3 immunoblots (Figure 8c). Interestingly, RSV-induced ROS production was highly
impaired in resistant populations showing an important adaptation towards the
oxidative stress after prolonged treatments (Figure
8a). To assess this adaptation, we analysed the antiproliferative effects
of H2O2 and showed that resistant cells were obviously less
sensitive to oxidative stress (Figure 8d).
Accordingly, we detected a loss of sensitivity of these cells towards doxorubicin,
which is known to partly damage cells through an oxidative stress (Supplementary Table S1). Altogether, these results
demonstrated the importance of RSV-induced ROS production on its indirect
DNA-damaging effects, subsequent transient anticancer effects and a long-term
adaptation of cancer cells towards oxidative stress.
Figure 8
Reactive oxygen species mediate resveratrol-induced DNA damage and subsequent
effects. (a) Levels of reactive oxygen species (ROS) in PROb and SW620
cells as well as on the resistant populations R2PROb and
R2SW620 analysed by flow cytometry after 24 h of treatment with
30 μM of resveratrol (R30). The probes used were
H2DCFDA and MitoSOX which respectively detect the global level of
ROS and the O2− produced by mitochondria. Cells were
also grown in the presence of the antioxidant-reduced glutathione (GSH),
N-Acetylcystein (NAC) and Trolox. (b) Effects of the
supplementation of media with the antioxidants described above on the viability of
cells treated with R30 for 24 h. (c) Effects of co-treatments of
PROb cells with R30 and the antioxidants described above on the activation of H2AX
and caspase-3 and on the expression of p21Cip1 assayed by
immunoblotting. (d) Antiproliferative activity of
H2O2 on colon cancer cells was determined by treatments
with the indicated concentrations of H2O2 for 18 h
and after release in fresh media for 72 h. Data shown in A, B and D are
means±S.D. of three independent experiments
Discussion
In the present report, we studied the effects of RSV towards CCR models in
vivo and in vitro. We found that RSV shares common properties with
DNA-damaging drugs widely used to treat cancer by inducing similar mechanisms of
resistance establishment. [11, 27] We subsequently showed that this was related to
an overproduction of ROS against which CCR progressively developed adaptive
mechanisms.It was initially reported that RSV reduces the tumour progression in in vivo
cancer models[28, 29] but these results were challenged by several groups showing
no beneficial effect of RSV. Many factors may be involved in these controversial
results, including the sensitivity of the models, the doses and administration routes
and the animal species used which could show various immune properties.[30, 31, 32, 33] One of the
main arguments is still the low bioavailability of RSV. More recently, studies by
Patel et al.[21] and Aires et
al.[22] showing that RSV metabolites
accumulate in colon and exert anticancer activity seem to corroborate the positive
argument. In the present report, pharmacological administrations of RSV were not able
to counteract the growth of CCR in vivo, although plasma concentrations of
free RSV and its metabolites were comparable with previous studies.[34, 35] In fact, we
showed that RSV could induce DNA damage in CCR as recently reported in head and neck
squamous carcinoma.[36] For the first time,
we showed that RSV triggered a temporal related DDR in vivo as well as its
phenotypic consequences, that is, senescence and apoptosis. In in vitro
studies, CCR cells transiently accumulated in S-phase of the diploid and tetraploid
cell cycle and it is now obvious that tetraploid populations must be considered as
they are often more resistant towards chemotherapies.[37] A recent report using tetraploid cells isolated after
mitotic inhibitors exposure has shown that RSV efficiently killed these cells, but
these models do not mimic RSV-induced polyploidisation by itself.[38] Indeed, the present report demonstrates that
long-term treatments of CCR cells with RSV led to the emergence of polyploid
populations which showed resistance towards its anticancer effects. We have already
described the occurrence of similar phenomena with the DNA-damaging agent cisplatin,
which led to resistance emergence through endoreduplication along with an induction
of senescence and a reversible polyploidisation.[39]Previous reports have described a pro-senescence activity of RSV towards cell
lines[11, 40] which were blocked in senescence in a p53-dependent manner. In
this study, cells escaped this state despite the fact that they both display a p53
transactivational activity (PROb cells are p53wt and SW620 cells are
overexpressing a p53mut active form). p53 may be one of the main factor
implicated in RSV cell line-dependent potential as its level and time of activation
have been recently shown to regulate the senescence/quiescence/apoptosis
balance[41]. Thus, this study
demonstrates that RSV induces more apoptosis in SW620 cells carrying a hyperactive
p53mut. Moreover, the transient senescence response observed is
comparable with studies reporting the implication of senescence in the resistance
mechanisms triggered by cancer cells towards DNA-damaging drugs.[39, 42, 43]We next demonstrated that RSV anticancer effects were linked to its ability to induce
the DDR as shown by the rapid activation of γH2AX. This was
concomitant with a rapid induction of a Chk1-related response and a delayed Chk2
activation, leading to an overall p53-dependent response. Inhibitors of
DDR-implicated kinases demonstrated that subsequent checkpoint and repair activations
were responsible for the maintenance of the viable polyploid cells, since their
inhibitions dramatically reduced polyploidy and sensitised cells to apoptosis.
Moreover, the early Chk1 response was consistent with the occurrence of a rapid
replication stress induction and its inhibition synergised with RSV in inducing DNA
damage and apoptosis as previously shown for other chemotherapies.[44] Importantly, the present report shows that
RSV's indirect DNA damaging properties and subsequent anticancer properties are
mostly related to an induction of ROS production as shown by co-treatments with
antioxidants. This statement was reinforced by the rapid induction of ATM, p16 and
p21 expressions, which have been recently reported to participate in the crosstalk
between ROS production and senescence.[45,
46, 47]The present work raises some doubts about the widely accepted antioxidant potential
of RSV. There is now a compelling evidence that this overall antioxidant effect is
probably an indirect consequence of its primary pro-oxidant potential. Similar
observations have been published with other polyphenols like
epigallocatechin-3-gallate and curcumin, linking their DNA damage-like effects to
their potential to induce ROS production.[48,
49] Here, populations of cells which have
been exposed to RSV during several weeks became more resistant to
H2O2 and doxorubicin (known to trigger oxidative stress),
and it is tempting to hypothesise that detoxifying systems are involved as shown for
other potent chemopreventive molecules.[50]To conclude, this study provides new insights into RSV as an anticancer compound
linking its in vitro effects to its potency in vivo, and
collectively these experiments suggest that a potential acquired resistance towards
RSV during prolonged treatment should be taken into account in the case of clinical
trials.
Materials and Methods
Chemical reagents and antibodies
Trans-RSV (>99% purity) was obtained from Tianjin Jianfeng
Natural Products (Tianjin, China). All other chemicals were obtained from Sigma
Aldrich (Saint Quentin-Fallavier, France) unless stated otherwise. Antibodies used
are described in the Supplementary Table S2.
Cell lines
The PROb cell line (DHD-K12-TRb, deposited at the European Collection of Animals
Cell Culture, ECACC, Salisbury, UK), obtained from a well-differentiated colon
carcinoma induced in the BD-IX rat strain[51], was cultured in RPMI 1640 medium supplemented with
10% foetal calf serum. The humancolon carcinoma SW620 and the normal rat
intestinal IEC18 cell lines (ECACC) were maintained in Dulbecco's modified
Eagle's medium containing 10% foetal calf serum.
Cell treatments
Cells were treated for indicated times with indicated concentrations of RSV
dissolved in the media containing a final amount of 0.1% ethanol or
mock-treated. RSV-resistant PROb and SW620 cells, named R2PROb and
R2SW620, respectively, were obtained by culturing exponentially
growing parental cell lines in a selective pressure of 30 μM
RSV during 2 months, resulting in RSV-resistant populations stable in time. To
determine the involvement of the DNA-damage pathways in RSV-mediated effects,
cells were either pre-treated for 2 h prior to RSV treatment with
2 mM caffeine known to inhibit the PIKKs, 2 μM of the
Chk1 inhibitor SB218078, 10 μM of the ATM inhibitor KU55933 or
10 μM of the DNA-PK inhibitor NU7026, all purchased from
Merck Chemicals (Nottingham, UK). To counteract RSV-induced ROS, cells were
pre-treated for 4 h with 10 mM of reduced glutathione or
N-Acetylcystein (a glutathione precursor), or 10 μM of
Trolox, a water-soluble derivative of vitamin E. H2O2
antiproliferative activity was determined by treating cells with concentrations
from 25–400 μM for 18 h and after a release in
fresh medium for 72 h.
Proliferation assays
Cells were seeded in quadruplicate in 24-well plates and treated with indicated
concentrations of chemicals 24 h later. After the indicated times, cells
were washed with PBS, stained with crystal violet (0.5% (w/v) crystal
violet in 25% (v/v) methanol) for 5 min and gently rinsed with
water three times. Absorbances were read at 540 nm after extraction of the
dye by 0.1 M sodium citrate in 50% ethanol.
Flow cytometry
Cell cycle analyses by BrdU incorporation were conducted as previously
described.[18] For H2AX
phosphorylation on Ser139 analyses, cells were fixed in 100% methanol on
ice for 15 min, washed in PBS, blocked for 20 min in PBS-1%
BSA and incubated with a rabbit anti-pSer139-H2AX antibody (1/1000 in PBS-BSA,
Santa-Cruz Biotechnology, CA, USA) for 1 h. After washes in PBS, cells were
incubated for 1 h with a secondary anti-rabbit Alexa-488 antibody
(1/500 in PBS-BSA, Invitrogen/Molecular Probes, Eugene, OR, USA). Cells
were then washed and the DNA counterstained with 50 μg/ml
propidium iodide for 30 min in the presence of 200-μg/ml
RNAse A. To measure the production of ROS, we used the probes
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) which
fluoresces when oxidised by intracellular ROS and MitoSOX which responds to
mitochondrial O2- (both obtained from Molecular Probes).
Briefly, cells were incubated with 10-μm H2DCFDA or MitoSOX
during 15 min, washed with PBS and immediately analysed by flow cytometry.
All the assays were monitored on a Galaxy flow cytometer (Partec, Münster,
Germany) and analysed with the FloMax software (Partec) on at least 100 00
cells.
Fluorescence microscopy
TdT-mediated dUTP Nick-End Labeling (TUNEL) and Hoechst 33342 stainings were used
to analyse nuclear morphologies according to the manufacturer's instructions
(DeadEnd Fluorometric TUNEL System, Promega, Charbonnières-les-Bains,
France). For in vitro assays, adherent and floating cells were cytospun
and phenotypes of nuclei were determined by analysing at least 300 cells per
experiment. For in vivo staining, tumours were cut in 6-μm
sections using a cryostat microtome, mounted on gelatinised slides, processed and
analysed by determining the mean pixels intensities of random microscopic fields
by using the ImageJ software (NIH).
Stainings for SA-β-gal activity revealed at pH 6.0 were performed as
previously reported.[52]
In vitro, cells were grown in 12-well plates on glass coverslips and
treated with RSV for the times indicated. In vivo, slides were analysed
as described above.
Tumour growth analyses in vivo
Exponentially growing PROb and SW620 cells were harvested and 106
(PROb) or 3 × 106 (SW620) cells were injected subcutaneously into
syngeneic BD-IX rats (PROb) or into NMRI-nu Nude mice (SW620; Janvier Labs,
Saint-Berthevin, France). Animals were individually treated per os by
administrating an appropriate amount of RSV. Amounts of RSV were weekly adapted to
corporal mass to obtain 40, 100 or 200 mg/kg per day treatments.
Treatments began at different tumour stages, from day 2 after cells inoculation
and from day 14. Tumour volumes were evaluated weekly using a calliper. Animal use
and handling were approved by the local veterinary committee and performed
according to European laws for animal experimentation.
Resveratrol plasma concentration measuremnts
Plasma samples were treated for 2 h at 37 °C with 200 U
of ß-glucuronidase (HP-2 type) in 0.5 ml of 0.2 M
acetate buffer; control samples were incubated with buffer alone. Each sample was
then acidified to pH 4.5, received carbamazepine as internal standard, and was
passed through a C18 Sep-Pak cartridge (Waters, Milford, MA, USA) pre-conditioned
with methanol and acetate buffer. After washing with acetate buffer, RSV
and/or its metabolites were eluted with 2 ml of methanol. After
evaporation, they were redissolved in ethanol for analysis. RSV assays were
performed on a reverse-phase Nucleosil C18 column (250 × 4.6 mm,
5 μm) from Alltech Associates (Deerfield, IL, USA) in a
Waters 625-LC system. Compounds were eluted from the column with a gradient
containing water and acetonitrile. The UV detector (Waters 486, Milford, MA, USA)
was set at 306 nm. RSV amounts were quantified with an SP4400 ChromJet integrator
(Spectra Physics, San Jose, CA, USA).
Western blotting
After the indicated treatments, adherent and floating cells were washed in PBS,
lysed in a Ripa buffer and western blot analyses were performed as previously
described.[18]
Statistical analysis
The in vitro data are expressed as the mean±S.D. of three
independent experiments. In vivo data are shown as median±the
first and the third quartiles. Statistical significances were evaluated either
with the Mann–Whitney or the t-test as required.
Authors: G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith Journal: Proc Natl Acad Sci U S A Date: 1995-09-26 Impact factor: 11.205
Authors: N C Jenkins; T Liu; P Cassidy; S A Leachman; K M Boucher; A G Goodson; G Samadashwily; D Grossman Journal: Oncogene Date: 2010-09-13 Impact factor: 9.867
Authors: Atanu Mondal; Apoorva Bhattacharya; Vipin Singh; Shruti Pandita; Albino Bacolla; Raj K Pandita; John A Tainer; Kenneth S Ramos; Tej K Pandita; Chandrima Das Journal: Mol Cell Biol Date: 2021-11-08 Impact factor: 5.069